Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 18/20 | 0.46 |
| ▸ | ESR1 | P03372 | 13/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365692 | 0.92 | PKLR (0.43) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL5112451 | 0.91 | NQO1 (0.48) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL5115673 | 0.88 | ESR2 (0.43) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL5337618 | 0.84 | ESR2 (0.49) | ESR2ESR1KDM4EALDH1A1GAA | |
| SCHEMBL5112371 | 0.84 | ESR2 (0.36) | ESR2MAOACASP1CASP7 | |
| SCHEMBL5125212 | 0.81 | MAOA (0.40) | KDM4EALDH1A1HPGDMAOAHSD17B10 | |
| SCHEMBL5125504 | 0.80 | CNR2 (0.32) | ESR2ESR1KDM4E | |
| SCHEMBL5114216 | 0.79 | CNR2 (0.32) | HPGD | |
| SCHEMBL5111271 | 0.77 | CSNK2A2 (0.36) | ESR2ESR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5125433 | 0.77 | NQO1 (0.38) | ESR2ESR1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384975-B2 | Substituted furochromenes, preparation thereof and their antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-06-10 | — | — | US | disclosed |
| US-20060148889-A1 | Substituted furochromenes, preparation thereof and their antiinflammatory action | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | disclosed |
| EP-1648902-A1 | SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005010007-A1 | SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION | PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148889-A1 | Substituted furochromenes, preparation thereof and their antiinflammatory action | CYP11B2, CYP11B1, LTC4S | ESR2 962/4885ESR1 1942/4885KDM4E 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.